Kyron.bio, a Paris‑based biotech startup, has raised €5.5 million in a seed funding round, as announced by the company in its official news release. The round was led by HCVC, with participation from Verve Ventures, Entrepreneur First, Saras Capital, and angel investors.
Details of the Funding
The investment will be used to advance and scale Kyron.bio’s proprietary glycan‑engineering platform, expand its team, and push forward with preclinical initiatives, according to the company’s announcement. This funding marks a significant step toward commercializing its technology for more effective and safer antibody‑based therapeutics.
What Kyron.bio Does
Kyron.bio specializes in precision control of N‑glycosylation—the attachment of sugar molecules to therapeutic proteins—in order to enhance drug safety, efficacy, and stability. Their platform combines engineered cell lines capable of precise glycosylation with a glycan‑engineering toolbox designed to ensure high uniformity in glycan structures. This promising innovation aims to reduce immune reactions and improve therapeutic consistency.
Context and Significance
This seed funding not only empowers Kyron.bio’s development pipeline and R&D expansion, it also underscores investor confidence in pioneering glyco‑engineering as a transformative approach in biologics. For women leaders in biotech, the story is particularly compelling: Kyron.bio was founded and is led by Dr. Emilia McLaughlin, representing a strong example of female leadership in cutting‑edge scientific entrepreneurship.
Conclusion
With €5.5 million in new capital and growing interest in precision biologics, Kyron.bio is well positioned to push forward its glycan‑engineering innovations. The leadership of Dr. Emilia McLaughlin and the backing of major biotech venture stakeholders underscore the growing momentum around diversity and innovation in life sciences.